Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Total Non-Current Liabilities (2017 - 2025)

Historic Total Non-Current Liabilities for Crinetics Pharmaceuticals (CRNX) over the last 5 years, with Q3 2025 value amounting to $121.0 million.

  • Crinetics Pharmaceuticals' Total Non-Current Liabilities rose 1644.64% to $121.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.0 million, marking a year-over-year increase of 1644.64%. This contributed to the annual value of $109.0 million for FY2024, which is 1320.66% up from last year.
  • As of Q3 2025, Crinetics Pharmaceuticals' Total Non-Current Liabilities stood at $121.0 million, which was up 1644.64% from $115.7 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' Total Non-Current Liabilities' 5-year high stood at $121.0 million during Q3 2025, with a 5-year trough of $96.2 million in Q4 2023.
  • For the 3-year period, Crinetics Pharmaceuticals' Total Non-Current Liabilities averaged around $108.0 million, with its median value being $105.6 million (2025).
  • Over the last 5 years, Crinetics Pharmaceuticals' Total Non-Current Liabilities had its largest YoY gain of 1644.64% in 2025, and its largest YoY loss of 1065.7% in 2025.
  • Quarter analysis of 3 years shows Crinetics Pharmaceuticals' Total Non-Current Liabilities stood at $96.2 million in 2023, then increased by 13.21% to $109.0 million in 2024, then grew by 11.02% to $121.0 million in 2025.
  • Its last three reported values are $121.0 million in Q3 2025, $115.7 million for Q2 2025, and $105.6 million during Q1 2025.